The noninterventional study NABUCCO evaluated effectiveness and safety of nab-paclitaxel in 697 patients with metastatic breast cancer (MBC) treated in routine care. The results confirm the clinical trial outcomes, the favorable benefiterisk profile of nab-paclitaxel, and the sustained global quality of life in patients with MBC in a real-world setting. Background: One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials have shown high efficacy and acceptable toxicity. Real-world data of nab-P in MBC, however, are still limited. Patients and Methods: The prospective multicenter noninterventional study NABUCCO collected data on the routine treatment of patients with MBC receiving nab-P in 128 sites across Germany. The primary objective was time to progression. Secondary objectives were overall response rate, overall survival, safety, and quality of life. Results: Between April 2012 and April 2015, a total of 705 patients with MBC at 128 active sites had been enrolled. A total of 697 patients had evaluable data with a median follow-up of 17.7 months. Median time to progression was 5.9 months (95% confidence interval, 5.6-6.4), overall response rate was 37.2%, and median overall survival was 15.6 months (95% confidence interval, 14.2-17.2). The results were similar in patients aged < 65 versus ! 65 years as well as in patients who received nab-P on a weekly or a triweekly schedule. The most frequently reported grade 3/4 adverse events were leukopenia (55, 7.9%), peripheral sensory neuropathy (30, 4.3%), and infections (29, 4.2%). Patients reported no apparent treatment-related impact on global quality of life. Conclusion: The results of the NABUCCO study confirm the clinical trial outcomes and the favorable safety profile of nab-P in patients with metastatic breast cancer in a real-world setting.
Introduction
Taxanes belong to the most effective chemotherapeutic agents for the treatment of metastatic breast cancer (MBC). 1 One of these taxanes is nab-paclitaxel (nab-P), which is approved for the treatment of MBC patients after failure of first-line therapy and when anthracycline-containing regimens are not indicated. In the pivotal 1 phase 3 trial published by Gradishar, 2 nab-P showed a significant prolongation of time to progression (TTP), a higher response rate, and a prolonged median overall survival (OS) compared to solvent-based paclitaxel. For patients with MBC, nab-P is approved on a onceevery-3-weeks (triweekly) schedule at a dosage of 260 mg/m 2 according to the current Summary of Product Characteristics (SmPC). A number of further trials have evaluated different patterns of use for nab-P, eg, treatment schedules, dose schemes and combinations with other antineoplastic agents, with the aim to optimize nab-Pebased therapy for metastatic and early breast cancer. [3] [4] [5] [6] Although nab-P monotherapy at a dose of 260 mg/m 2 applied triweekly is indicated for the treatment of patients with MBC according to SmPC, emerging evidence suggests that nab-P may be administered weekly in a dose of 150 mg/m 2 or combined with other agents, offering flexibility in dosing and adjusting the treatment according to the individual clinical situation. nab-P has also been shown to be safe and effective in patients aged 65 years or older and has received approval in other entities like non-small cell lung cancer and pancreatic cancer. [7] [8] [9] [10] [11] [12] nab-P provides a favorable safety profile compared to solvent-based paclitaxel. 2 Neuropathy is a frequent and dose-limiting side effect during taxane therapy and has also been reported during treatment with nab-P.
13,14
Such neuropathic symptoms are often permanent and strongly affect the patients' quality of life (QoL). [14] [15] [16] [17] In clinical trials, manageable toxicities and preserved QoL have been reported during treatment with nab-P. 17 However, data on nab-P treatment and patients' QoL in routine care are still scarce.
Patients and Methods

Study Design
The prospective, noncomparative, multicenter noninterventional study (NIS) NABUCCO collected data of 697 patients with MBC in routine clinical practice in 128 oncology outpatient centers across Germany. The study was approved by the responsible ethics committee and is registered at ClinicalTrials.gov (NCT01689610). Written informed consent was obtained from all patients before study entry. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was conducted according to the recommendations of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany).
Eligible patients were women aged ! 18 diagnosed with MBC and assigned to palliative nab-P therapy as per current SmPC, ie, first-line treatment had failed and standard anthracycline-containing therapy was not indicated. The prescription of the study medication was independent from the decision to include the patient into the study. The course of treatment with nab-P reflected routine clinical practice in which the treating physicians were held responsible for the choice of dosing and treatment schedule.
Study End Points
The primary end point was TTP, defined as the time from start of treatment until disease progression or death caused by tumor progression. Secondary end points were OS, overall response rate (ORR) as per assessment of the treating physician, safety, and QoL. QoL was assessed using the Functional Assessment of Cancer TherapyeGeneral (FACT-G), 18 the breast cancerespecific module (FACT-B), the taxane-specific module (FACT-Taxane), and the RKI (Robert-Koch-Institute, Germany) pain questionnaire. 19 
Study Treatment
Treatment was continued until disease progression, unacceptable toxicity, or patient refusal. The maximum treatment documentation period per patient was 6 months; afterward patients were followed up on disease progression and subsequent treatment lines until the end of the treatment documentation of the last patient. Follow-up for OS was performed. Routine clinical assessment comprised the complete medical history, physical examination including Eastern Cooperative Oncology Group (ECOG) performance status, and a neurologic assessment. Neurologic examination and further toxicity assessments (in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.03) were completed at each patient visit. Patients filled in QoL questionnaires at prespecified time points at start of nab-P therapy, and again at 3 and 6 months after start of therapy. Tumor assessments were performed according to routine clinical practice, and clinical responses were evaluated as per assessment of the treating physician.
Treatment schedules were categorized by medical review according to the following 3 definitions: (1) ; and (3) all other cases. All treatment-emergent adverse events (AEs) were recorded up to 30 days after the end of the treatment documentation period regardless of the causal attribution.
Statistical Analysis
All statistical analyses were conducted using the full analysis set (FAS) defined as and including all patients with at least one administration of nab-P. All variables were analyzed in a descriptive manner. Continuous variables were listed as number of observations, mean, standard deviation, median, 25% and 75% quartile, and minimumemaximum. Categorical variables were presented as absolute and relative frequencies within single categories including an individual "missing" category. Subgroup analyses were considered exploratory. TTP and OS were estimated by the Kaplan-Meier method. Duration of follow-up was calculated using the reverse Kaplan-Meier estimate. 20 An exploratory analysis was performed using a multivariate Cox (proportional hazards) regression model to identify potential prognostic significance of covariates on effectiveness of treatment (TTP). Selected covariates included line of palliative chemotherapy, administration mode, age, receptor status, ECOG, and presence of distant metastases at inclusion. Covariates that were not found to be statistically significant were excluded from multivariate analysis (ie, presence of any comorbidity, tumor stage, lymph node status, and taxane before treatment). Differences between covariates were presented as hazard ratios, including 95% confidence intervals (CIs) and P values. All statistical analyses were e1324 -Clinical Breast Cancer December 2018
Results of NABUCCO performed according to the predefined statistical analysis plan using SAS 9.4 software (SAS Institute, Cary, NC). As a result of the character of a NIS, no formal sample size calculation was performed. Approximately 70,000 women are diagnosed with breast cancer in Germany every year, 21 and about 20% to 30% of patients experience relapse or develop metastases. Under the assumption that every study site recruits 7 patients with MBC within the first 3 years, data on approximately 700 patients receiving treatment with nab-P were planned to be evaluated in the course of the study.
Results
Patients
Between April 2012 and April 2015, a total of 705 women with MBC assigned to palliative treatment with nab-P were enrolled onto 128 outpatient oncology centers in Germany. For 8 patients, no nab-P treatment had been documented, and therefore they were excluded from the FAS. Individual patients were observed for 6 months, followed by a 30-day safety follow-up period. The FAS finally comprised 697 patients, 514 of whom entered the follow-up period ( Figure 1 ). A total of 335 patients entered an additional longterm follow-up period for survival evaluation (until 9 months after the last patient had finished treatment observation).
Patient characteristics are presented in Table 1 . Median age of the patients was 62.3 years (range, 29.9-89.3 years), and 291 patients (41.8%) were aged ! 65 years. The ECOG performance status in the age group < 65 years was 0 and 1 in 52.0% and 38.7% of the patients, respectively. For the age group ! 65 years, the ECOG performance status was 0 and 1 in 38.1% and 51.2% of the patients, respectively. A total of 49 patients (7.0%) presented with ECOG ! 2.
Most of the patients had ! 1 documented concomitant disease (70.2%), and nearly all patients presented with metastatic disease (96.3%). The most frequently reported metastatic sites were bone (58.0%), liver (44.2%), lung (37.7%), and lymph nodes (31.3%). The overall median time from diagnosis of breast cancer to start of nab-P therapy was 65.2 months-57.1 months in patients aged < 65 years and 76.2 months in patients aged ! 65 years. The overall median time from first diagnosis of metastases to start of nab-P therapy was 17.4 
Time to Tumor Progression
After a median follow-up of 17.7 months, the median TTP for all patients was 5.9 months (95% CI, 5.6-6.4) (Figure 2A) , with a 
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median TTP of 7.1 months (95% CI, 6.0-8.6) for first-line, 6.0 (95% CI, 5.5-7.3) for second-line, 5.6 months (95% CI, 4.6-6.7) for third-line and 5.2 months (95% CI, 4.2-5.6) for fourth-line or higher treatment ( Figure 2D ). Median TTP was observed to be slightly shorter in patients with prior exposure to taxanes: 5.6 months (95% CI, 5.3-6.0) compared to 6.9 months (95% CI, 5.9-7.9) in patients without prior taxane receipt before treatment (Tables 2 and 3 (Figure 3 ). This difference in TTP could also be seen in the corresponding TTP curves: median TTP was 4.9 months for triple-negative tumors and 6.2 months for HR þ / HER2 À tumors ( Figure 2C) . The model showed a higher risk of progression for patients who had distant metastases at inclusion and patients who had received ! 3 prior chemotherapies before nab-P treatment (vs. nab-P in first-line treatment; Figure 2D and Figure 3 ). There was no substantial difference in TTP between , and the Cox model estimated no significant difference in the risk of progression ( Figure 2E and Figure 3 ). Taxane pretreatment was not retained in the model because it had not been significant at the 5% level during the model-building process.
Overall Survival
Median OS for all patients was 15.6 months (95% CI, 14.2-17.2) ( Table 2 ).
Overall Response Rate
The ORR for all patients was 37.2% (3.9% complete response, 33.3% partial response) based on the assessment of the treating physician. A total of 31.1% of patients were documented with stable disease; in 12.3% of the patients, no assessment was documented (Table 3) . Interestingly, the ORR differed between the age groups with an ORR of 41.1% in patients aged < 65 years and 31.6% in patients aged ! 65 years. As expected, patients in advanced treatment lines had a lower ORR than patients receiving nab-P as firstline chemotherapy treatment (ORR first line, 46.1%; second line, 32.0%; third line, 31.9%; fourth line or higher, 29.0%). No 
Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio; PS ¼ performance status; TNBC ¼ triple-negative breast cancer. 
Safety
Median duration of nab-P therapy was 18.3 weeks (25-75% quartile 12.0-25.6 weeks) ( Table 4) . Of all patients in the FAS (n ¼ 697), the majority experienced at least one AE (583, 83.6%). The most common AEs (! 10%) were peripheral sensory neuropathy (39.6%), fatigue (20.8%), decreased white blood cells (17.9%), nausea (15.1%), peripheral motor neuropathy (12.8%), alopecia (11.8%), and diarrhea (11.5%). AEs of particular interest such as febrile neutropenia were reported in 0.9%, lung infection in 1.7%, and sepsis in 0.7% of patients. A total of 239 patients (34.3%) developed an CTCAE grade 3/4 AE. Of these patients, 503 (72.2%) experienced an AE possibly related to nab-P (adverse drug reactions, ADRs). The most frequently reported grade 3/4 AEs are listed in Table 5 . ADRs grade 3/4 (! 1.0%) were leucopenia (7.5%), peripheral sensory neuropathy (4.2%), neutropenia (4.0%), anemia (1.6%), nausea (1.3%), fatigue (1.3%), and peripheral motor neuropathy (1.0%). ADRs of particular interest were febrile neutropenia (0.9%), lung infection (0.3%), sepsis (0.1%), and paresthesia (0.1%). Regarding neurotoxic events, grade 3/4 ADRs were observed in 5.2% of patients in total; however, no grade 4 peripheral sensory neuropathy events were reported (Supplemental Table 1 in the online version). Regarding treatment schedules, leucopenia and neutropenia CTCAE grade 3/4 were more frequent in patients treated according to the weekly administration mode (9.8% vs. 1.5% and 5.1% vs. 0.5%, respectively). Other AEs, especially neurotoxicity-related events, did not differ substantially. The median dose intensity of nab-P was 76.8 mg/m 2 per week (reference for dose intensity as per SmPC: 86.7 mg/m 2 per week), with no obvious differences in average weekly dose intensities per week), and number of patients without therapy modification (37.2% vs. 32.0%), indicating that treatment was tolerated to the same extent in both age groups (Table 7) . Regarding treatment patterns, however, therapy modifications were more frequent in patients receiving the weekly schedule. The percentage of patients with at least one skipped administration due to adverse reactions to nab-P was 24.4% and 6.2% in the weekly and the triweekly administration modes (Table 6) , respectively, and thus differed substantially. A reason might be that skipping of one dose in a weekly schedule does not affect the total dose as much as skipping a dose in the triweekly administration mode. The fatal serious AEs (n ¼ 51) during treatment and the 30-day follow-up period were progression of the underlying breast cancer disease (n ¼ 24; 2 of them were also reported with organ dysfunction CTCAE grade 5 and fatal liver failure) or deterioration of general health status (general disorders, n ¼ 6; multiorgan failure, n ¼ 4). Five patients died of respiratory events (dyspnea, n ¼ 2; respiratory failure, n ¼ 2; pleural effusion, n ¼ 1) and 5 patients of infections (pneumonia, n ¼ 3, sepsis, n ¼ 2). Three patients died of acute renal failure, one of which was associated with acute diarrhea, and 2 patients died of hepatic failure. For 3 patients, other causes of death were documented (heart failure, vascular disorders [aortic aneurysm], and hemolytic anemia).
Quality of Life
On the basis of patient-reported outcomes, there was no obvious impact of nab-P therapy on QoL. FACT-G and FACT-B global scores were almost not affected during the treatment with nab-P (Supplemental Figure 1 in the online version) . However, taxaneinduced symptoms increased in a clinically relevant manner and were persistent throughout the observation period, as indicated by a reduction in the median FACT-Taxane subscale score from 52.3 (25-75% quartile, 45-59) at start of nab-P therapy to 40.0 (25-75% quartile, 30-51) after 6 months (Supplemental Figure 1 in the online version). Patients reported that symptoms of pain in fingers and toes increased throughout the study until the end of the observation period compared to baseline. However, symptoms in the back and bones in particular had already been present at start of therapy (Supplemental Figure 2 in the online version).
Discussion
Since the pivotal study by Gradishar et al 2 published in 2005 assessing nab-P 260 mg/m 2 on a triweekly schedule in patients with MBC, treatment strategies both for early and advanced breast cancer have clearly changed with regards to the use of taxane-containing regimens, both in the adjuvant and palliative settings. For HR þ / HER2 À MBC with tumor progression after first-line therapy, nab-P has become a standard therapy because of its higher response rates and improved survival compared to solvent-based paclitaxel. 2 Realworld data on nab-P treatment in MBC, however, are still limited.
The results of the NABUCCO study confirm the clinical trial efficacy and safety outcomes of nab-P in patients with MBC in the real-world setting, despite a heterogeneous and an overall older and Data are presented as n (%) unless otherwise indicated. Triweekly indicates administration once every 3 weeks.
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Clinical Breast Cancer December 2018 -e1331 more comorbid patient population in routine clinical care. The benefit from nab-P for patients aged ! 65 years is similar to their younger counterparts. Safety issues in terms of frequent dose reductions or therapy interruptions were increased only to a limited extent. Similar favorable response data, particularly in an elderly patient group (age > 70 years), were reported in another real-world study conducted in Austria, in which an ORR of 50% in patients aged >70 years (n ¼ 20) was reported compared to 37% in patients aged 70 years (n ¼ 113). 22 We found promising response rates both in patients pretreated with taxane-based chemotherapy (36%) and patients without taxane pretreatment (39%). Thus, our data are in line with another real-world study reporting significant antitumor activity of nab-P (ORR 23.8%) in patients pretreated with adjuvant or palliative taxanes. 23 Concerning treatment patterns, recent clinical trial efforts to maintain efficacy while limiting toxicity have focused on the optimization of nab-P schedule and dose. A US community-based realworld cohort study reported that nab-P was primarily used on a weekly schedule with favorable outcome. 24 Also in our study, weekly administration schedules were more frequently used than triweekly schedules, as recommended in the SmPC. However, there was no difference in outcome between the 2 administration modes, eg, ORR 39.1% weekly versus 33.0% triweekly, TTP 6.0 versus 5.7 months, and OS 16.3 months versus 15.1 months, respectively. These outcomes are in line with the real-world data from approximately 200 patients published by Bernardo et al in 2017. 25 While different dosing and administration schedules of nab-P in first-and further-line therapy may enable a broader therapeutic approach and an individually tailored therapy based on "disease-related factors and patient attitudes" as: stated by Bernardo et al, 25 the optimal dosing schedule for treatment of MBC still needs to be determined.
Findings from a randomized study by Gradishar et al 4 
in 2009
suggested that nab-P provided weekly for 3 weeks at a dose of 150 mg/m 2 followed by 1 week of break is more effective in terms of progression-free survival than is 100 mg/m 2 nab-P provided weekly.
With regards to the choice of administration mode, it is important to identify both disease-and patient-related factors that could affect therapy choice and outcome. Dosing modifications and the use of different dosing schedules according to the biologic aggressiveness of disease and the overall patient condition (for patients unable to receive the licensed dose) are recommended. 26 Despite the poorer overall prognosis of patients with TNBC, an area of high unmet medical need, we observed a promising outcome of nab-P therapy in this difficult-to-treat patient group. Our results on median TTP (4.9 months) cannot be compared directly but were in line with the results from another real-world study, where time to treatment discontinuation was 3.3 months with nab-P in the TNBC cohort. 27 Additionally, recent clinical trials with nab-P demonstrating high pathologic complete response rates in the neoadjuvant setting in early stage breast cancer, particularly in the difficult-to-treat subgroup of TNBC, are encouraging. 28, 29 Considering the safety of nab-P treatment for patients with MBC, the NIS NABUCCO observed a favorable riskebenefit profile in the real-world setting. The safety profile of nab-P was consistent with safety data published in past clinical trials, including the registrational phase III trial. The most common AEs were similar to those reported in clinical trials, although the NIS setting of this study per se limits comparability to other clinical trial data. In most cases safety issues were manageable, and our results reflect acceptable tolerability of nab-P therapy. Grade 3/4 neutropenia was rare (< 5%) and febrile neutropenia uncommon (< 1.0%). The most common grade 3/4 nonhematologic AE associated with nab-P was peripheral neuropathy. Treatment-related peripheral sensory neuropathy of all grades was reported in 37.6% of the patients and thus remained an important issue. Peripheral motor neuropathy of all grades was documented in 11.5% of the patients. Grade 3/4 neurotoxic AEs in particular encompassed peripheral sensory neuropathy (4.3% of the patients, no grade 4), peripheral motor neuropathy (1.1%; 0.1% grade 4), and paresthesia (0.1%). The incidence of neurotoxic events was fewer compared to the incidence of neurotoxic events reported in the pivotal CA012 trial, which may be caused by an underreporting effect within the NIS NABUCCO in comparison to the pivotal trial with careful monitoring. 2, 30 However, the underreporting effect might have minor impact in this study because of a specific focus on reporting of neurotoxic Results of NABUCCO e1332 -Clinical Breast Cancer December 2018
effects. Obviously, taxane-induced neurotoxicity had an impact on the patients' QoL. Peripheral sensory neuropathy was the main drug-related toxicity that increased steadily during the course of therapy. However, treatment discontinuations due to polyneuropathy were rare. In 0.7% of patients, a neurotoxic CTCAE grade 3/4 AE led to a dose reduction of nab-P, in 1.0% of patients to an interruption in therapy, and in 1.7% of patients to a permanent discontinuation of nab-P therapy, respectively. According to the patient-reported outcomes, taxane-induced complaints persisted until the end of the 6-month observation period. The global QoL scores assessed from FACT-G and FACT-B questionnaires, however, were not affected as reported by the patients during the first 6 months of treatment.
Because of the single-arm nature of NABUCCO NIS, certain limitations arise, including known and unknown biases in patient selection, incidence of comorbidities, and confounders. Furthermore, subgroup analyses were exploratory in character, and no stratified randomization was performed. Therefore, when interpreting differences in subgroups, it should be considered that other factors not evaluated might have had an impact as well. A direct comparison of the effectiveness as assessed in this NIS to the efficacy reported in clinical trials is therefore limited. In addition, the response rate was evaluated on the basis of the investigators' assessment in routine clinical practice, not strictly following the Response Evaluation Criteria in Solid Tumors. The obtained safety data in this NIS were consistent with those reported in clinical trials, although the NIS setting of this study per se limits comparability to clinical trial data.
Conclusion
The results of the NABUCCO study confirm previous clinical trial outcomes, the favorable benefiterisk profile of nab-P, and the sustained global QoL in patients with MBC in a real-world setting. nab-P was effective and well tolerated both in elderly women (aged ! 65 years) and in patients with taxane-refractory disease.
Clinical Practice Points
nab-P is approved for treatment of MBC on a triweekly schedule (260 mg/m 2 ) on the basis of results from the pivotal phase 3 trial in which treatment with this regimen significantly increased patients' progression-free survival compared to solvent-based paclitaxel. Our data from routine clinical practice support a broader range of dosing and administration schedules in postmarketing use of nab-P than recommended in the SmPC. The outcome data suggest a weekly regimen to be comparable in effectiveness and safety to the triweekly regime. In the real-world setting, the physicians decided to use nab-P in first-and later-line treatment and not only as second-line therapy. nab-P was effective and well tolerated both in elderly (aged ! 65 years) and in patients with taxane-refractory disease. There has not been a finding in the course of the 6-month treatment observation period that would suggest a new safety signal in these subsets of patients. AEs were generally rare and were manageable, with an unaffected QoL. The outcome results of the NIS NABUCCO study may be used to refine treatment guidelines of nab-P with regards to administration modes, the treatment of elderly, and the treatment lines in which nab-P might be used. 
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